These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 20003640)

  • 21. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab.
    Mitchell I; Tough S; Gillis L; Majaesic C
    Pediatr Pulmonol; 2006 Dec; 41(12):1167-74. PubMed ID: 17058279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variation in timing of respiratory syncytial virus outbreaks: lessons from national surveillance.
    Panozzo CA; Fowlkes AL; Anderson LJ
    Pediatr Infect Dis J; 2007 Nov; 26(11 Suppl):S41-5. PubMed ID: 18090199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of palivizumab prophylaxis on respiratory syncytial virus hospitalizations in high risk Alaska Native infants.
    Singleton R; Dooley L; Bruden D; Raelson S; Butler JC
    Pediatr Infect Dis J; 2003 Jun; 22(6):540-5. PubMed ID: 12799511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].
    Resch B; Müller W
    Klin Padiatr; 1999; 211(6):450-5. PubMed ID: 10592925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RSV vaccine in development: assessing the potential cost-effectiveness in the Dutch elderly population.
    Meijboom MJ; Pouwels KB; Luytjes W; Postma MJ; Hak E
    Vaccine; 2013 Dec; 31(52):6254-60. PubMed ID: 24148573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE; Mahle WT
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemiology of respiratory syncytial virus infection in northern Taiwan, 2001-2005 -- seasonality, clinical characteristics, and disease burden.
    Lee JT; Chang LY; Wang LC; Kao CL; Shao PL; Lu CY; Lee PI; Chen JM; Lee CY; Huang LM
    J Microbiol Immunol Infect; 2007 Aug; 40(4):293-301. PubMed ID: 17712463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Seasonal variation of maternally derived respiratory syncytial virus antibodies and association with infant hospitalizations for respiratory syncytial virus.
    Stensballe LG; Ravn H; Kristensen K; Meakins T; Aaby P; Simoes EA
    J Pediatr; 2009 Feb; 154(2):296-8. PubMed ID: 19150677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit.
    McCormick J; Tubman R
    Pediatr Pulmonol; 2002 Oct; 34(4):262-6. PubMed ID: 12205567
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks.
    Figueras-Aloy J; Carbonell-Estrany X; Quero-Jiménez J; Fernández-Colomer B; Guzmán-Cabañas J; Echaniz-Urcelay I; Doménech-Martínez E;
    Pediatr Infect Dis J; 2008 Sep; 27(9):788-93. PubMed ID: 18664927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Substantial variability in community respiratory syncytial virus season timing.
    Mullins JA; Lamonte AC; Bresee JS; Anderson LJ
    Pediatr Infect Dis J; 2003 Oct; 22(10):857-62. PubMed ID: 14551484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are meteorological parameters associated with acute respiratory tract infections?
    du Prel JB; Puppe W; Gröndahl B; Knuf M; Weigl JA; Schaaff F; Schmitt HJ
    Clin Infect Dis; 2009 Sep; 49(6):861-8. PubMed ID: 19663691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
    Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O
    Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Respiratory syncytial virus risk factors in late preterm infants.
    Lanari M; Silvestri M; Rossi GA
    J Matern Fetal Neonatal Med; 2009; 22 Suppl 3():102-7. PubMed ID: 19925369
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
    Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recurrent wheezing after respiratory syncytial virus or non-respiratory syncytial virus bronchiolitis in infancy: a 3-year follow-up.
    Valkonen H; Waris M; Ruohola A; Ruuskanen O; Heikkinen T
    Allergy; 2009 Sep; 64(9):1359-65. PubMed ID: 19416146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants: potential for savings.
    Marchetti A; Lau H; Magar R; Wang L; Devercelli G
    Clin Ther; 1999 Apr; 21(4):752-66. PubMed ID: 10363740
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
    Lacaze-Masmonteil T; Rozé JC; Fauroux B;
    Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of respiratory syncytial virus infection as a cause of lower respiratory tract infection in children younger than 3 years of age in Japan.
    Kaneko M; Watanabe J; Kuwahara M; Ueno E; Hida M; Kinoshita A; Sone T
    J Infect; 2002 May; 44(4):240-3. PubMed ID: 12099731
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.